Advances in the Treatment of Thoracic Malignancies
Saturday, March 3, 2012
7:30 am – 3:00 pm
Dana-Farber Cancer Institute
Yawkey Center for Cancer Care
3rd Floor, Rooms 306-307
Boston, MA
Offered by Dana-Farber/Brigham and Women's Cancer Center and Harvard Medical School Department of Continuing Education
Quicklinks
Course Objectives | Agenda | Faculty
Credits | Registration Information
Course Overview & Objectives
Treatment decisions for lung cancers have become increasingly complex due to rapid growth in clinical and scientific knowledge related to these diseases. This course is designed to provide medical, radiation, and surgical oncologists, nurse practitioners, and other interested clinicians with the tools and knowledge to apply the latest findings into clinical practice. It will help practitioners understand how to incorporate molecular diagnostics into treatment decisions, apply new staging methodologies, utilize new targeted therapies and deliver individualized, multimodal treatment strategies for patients. Faculty will use lectures, panel discussions and case presentations to share advances in diagnosis and treatment as well as to highlight areas of consensus and controversy in the multidisciplinary management of thoracic cancer.
Learning Objectives: At the conclusion of the course, attendees will be able to: understand and apply new research that is changing lung cancer care; identify clinical research opportunities for patients; and evaluate and incorporate molecular information into clinical practice for personalized patient care.
About the Lowe Center for Thoracic Oncology at Dana-Farber/Brigham and Women's Cancer Center
The Lowe Center for Thoracic Oncology provides expert care for patients with lung cancer, malignant mesothelioma, mediastinal and thymic tumors, and metastatic cancers to the chest. Our multidisciplinary team consisting of thoracic surgeons, medical and radiation oncologists, pulmonary disease specialists, radiologists, pathologists, nurses, physical therapists, respiratory therapists, dieticians, and social workers, offers advanced care, tailored to meet the needs of each patient, in order to maximize patient outcomes and quality of life.
Our center is also a leader in clinical and laboratory research to identify innovative treatment strategies for thoracic malignancies. A strategy of personalized therapy permeates our research, with clinical trials developed to identify the most promising new cancer drugs and deliver them to the patients most likely to benefit from them.
Agenda
7:30 am
Registration and Continental Breakfast
8:00 am
Welcome/Introduction to Topics and Learning Objectives
8:10 am
Lung Cancer Screening: Current Thoughts and Controversies
Mizuki Nishino, MD
8:30 am
Panel Discussion with Q&A: Lung Cancer Screening
David M. Jackman, MD; Bruce E. Johnson, MD; Yolonda L. Colson, MD, PhD
8:50 am
Advances in Chemotherapy for Metastatic NSCLC
J. Paul Marcoux, II, MD
9:10 am
Panel Discussion with Q&A: Chemotherapy for Metastatic NSCLC
J. Paul Marcoux, II, MD; Michael S. Rabin, MD; David M. Jackman, MD
9:40 am
Erlotinib and Crizotinib in Molecularly Identified Cohorts
Pasi A. Jänne, MD, PhD
10:00 am
Panel Discussion with Q&A: Overview of Current and Potential Role of Molecular Genotyping in Lung Cancer
Bruce E. Johnson, MD; Pasi A. Jänne, MD, PhD; Stacy Gray, MD, AM
10:30 am
Break
10:40 am
Panel Discussion with Q&A: External Beam RT, IMRT, SBRT, Hypofractionated RT—When Each Should Be Used
David E. Kozono, MD, PhD; Aileen B. Chen, MD, MPP; Raymond H. Mak, MD
11:10 am
Panel Discussion with Q&A: Minimally Invasive Surgical Techniques in Treating/Evaluating Lung Cancer
Scott J. Swanson, MD; Yolonda L. Colson, MD, PhD; Jon O. Wee, MD, FACS
11:40 am
Case Discussions with Q&A: Surgery in Oligometastatic Disease
Scott J. Swanson, MD; Bruce E. Johnson, MD; Michael S. Rabin, MD; David E. Kozono, MD, PhD
12:00 pm
Case Discussions with Q&A: Mesothelioma
David M. Jackman, MD; Scott J. Swanson, MD; Elizabeth H. Baldini, MD, MPH
12:20 pm
Lunch
1:20 pm
Symptom Management in NSCLC, with Q&A
Janet L. Abrahm, MD
2:00 pm
Updates in SCLC, Carcinoid, and Ongoing Clinical Trial Efforts, with Q&A
Leena Gandhi, MD, PhD
2:30 pm
Case Discussions with Q&A: Treating Brain Metastases in NSCLC and SCLC
Aileen B. Chen, MD, MPP; Stephanie E. Weiss, MD; Stephanie Heon, MD
3:00 pm
Wrap-up
Faculty
Bruce E. Johnson, MD, Course Co-Director
Director, Lowe Center for Thoracic Oncology
Dana-Farber/Brigham and Women's Cancer Center;
Professor of Medicine
Harvard Medical School
Leena Gandhi, MD, PhD, Course Co-Director
Medical Oncologist, Thoracic Oncology
Dana-Farber/Brigham and Women's Cancer Center;
Instructor in Medicine
Harvard Medical School
Janet L. Abrahm, MD
Chief, Division of Adult Palliative Care
Dana-Farber/Brigham and Women's Cancer Center;
Professor of Medicine
Harvard Medical School
Elizabeth H. Baldini, MD, MPH
Director, Radiation Oncology, Thoracic Oncology
Dana-Farber/Brigham and Women's Cancer Center;
Associate Professor of Medicine
Harvard Medical School
Aileen B. Chen, MD, MPP
Radiation Oncologist, Thoracic Oncology
Dana-Farber/Brigham and Women's Cancer Center;
Instructor in Radiation Oncology
Harvard Medical School
Yolonda L. Colson, MD, PhD
Surgical Oncologist, Thoracic Oncology
Director, Women’s Lung Cancer Program
Dana-Farber/Brigham and Women’s Cancer Center;
Associate Professor of Surgery,
Harvard Medical School
Stacy W. Gray, MD, AM
Medical Oncologist, Thoracic Oncology
Dana-Farber/Brigham and Women's Cancer Center;
Instructor in Medicine, Harvard Medical School
Stephanie Heon, MD
Medical Oncologist, Thoracic Oncology
Dana-Farber/Brigham and Women's Cancer Center;
Instructor in Medicine
Harvard Medical School
David M. Jackman, MD
Medical Oncologist, Thoracic Oncology
Dana-Farber/Brigham and Women's Cancer Center;
Assistant Professor of Medicine
Harvard Medical School
Pasi A. Jänne, MD, PhD
Medical Oncologist, Thoracic Oncology
Director, Translational Research
Dana-Farber/Brigham and Women's Cancer Center:
Associate Professor of Medicine
Harvard Medical School
David E. Kozono, MD, PhD
Radiation Oncologist, Thoracic Oncology
Dana-Farber/Brigham and Women's Cancer Center;
Instructor in Radiation Oncology
Harvard Medical School
Raymond H. Mak, MD
Radiation Oncologist, Thoracic Oncology
Dana-Farber/Brigham and Women’s Cancer Center;
Instructor in Radiation Oncology,
Harvard Medical School
J. Paul Marcoux, II, MD
Medical Director, Lowe Center for Thoracic Oncology
Dana-Farber/Brigham and Women's Cancer Center;
Instructor in Medicine
Harvard Medical School
Mizuki Nishino, MD
Radiologist
Dana-Farber/Brigham and Women's Cancer Center;
Assistant Professor of Radiology
Harvard Medical School
Michael S. Rabin, MD
Clinical Director, Lowe Center for Thoracic Oncology
Dana-Farber/Brigham and Women's Cancer Center;
Assistant Professor of Medicine
Harvard Medical School
Scott J. Swanson, MD
Chief Surgical Officer
Dana-Farber/Brigham and Women's Cancer Center;
Professor of Surgery
Harvard Medical School
Jon O. Wee, MD, FACS
Co-Director, Minimally Invasive Thoracic Surgery
Dana-Farber/Brigham and Women's Cancer Center;
Instructor in Medicine, Harvard Medical School
Stephanie E. Weiss, MD
Radiation Oncologist, Thoracic Oncology
Dana-Farber/Brigham and Women's Cancer Center;
Instructor in Radiation Oncology
Harvard Medical School
Harvard Medical School (HMS) adheres to all ACCME Essential Areas, Standards, and Policies. It is HMS’s policy that those who have influenced the content of a CME activity (e.g. planners, faculty, authors, reviewers and others) disclose all relevant financial relationships with commercial entities so that HMS may identify and resolve any conflicts of interest prior to the activity. These disclosures will be provided in the activity materials along with disclosure of any commercial support received for the activity. Additionally, faculty members have been instructed to disclose any limitations of data and unlabeled or investigational uses of products during their presentations.
CME Credits
The Harvard Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing education for physicians.
The Harvard Medical School designates this live activity for a maximum of 5.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Registration Information
Registration Fee: $75.00 (non-refundable).
Registration fee includes: continental breakfast, lunch, course materials, and complimentary parking.
To register by mail
Send completed registration form and check made payable to DF/BWCC to the address below:
Thoracic Cancer CME
Attn: Kamira Wooten
450 Brookline Avenue, OS 381
Boston, MA 02215
The registration form must be postmarked no later than February 17, 2012.
If you have food allergies, or if you require accommodations such as an ASL interpreter, materials in alternative format or wheelchair access, please email kwooten@partners.org or call 800-553-3787.
For directions to Dana-Farber, please visit: www.dana-farber.org/directions.
